264 related articles for article (PubMed ID: 24475282)
1. Activation of ERα signaling differentially modulates IFN-γ induced HLA-class II expression in breast cancer cells.
Mostafa AA; Codner D; Hirasawa K; Komatsu Y; Young MN; Steimle V; Drover S
PLoS One; 2014; 9(1):e87377. PubMed ID: 24475282
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.
Satoh A; Toyota M; Ikeda H; Morimoto Y; Akino K; Mita H; Suzuki H; Sasaki Y; Kanaseki T; Takamura Y; Soejima H; Urano T; Yanagihara K; Endo T; Hinoda Y; Fujita M; Hosokawa M; Sato N; Tokino T; Imai K
Oncogene; 2004 Nov; 23(55):8876-86. PubMed ID: 15467734
[TBL] [Abstract][Full Text] [Related]
3. Repression of IFN-gamma induction of class II transactivator: a role for PRDM1/Blimp-1 in regulation of cytokine signaling.
Tooze RM; Stephenson S; Doody GM
J Immunol; 2006 Oct; 177(7):4584-93. PubMed ID: 16982896
[TBL] [Abstract][Full Text] [Related]
4. IFN-gamma inducibility of class II transactivator is specifically lacking in human tumour lines: relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes.
Lu Y; Tschickardt ME; Schmidt BJ; Blanck G
Immunol Cell Biol; 1997 Aug; 75(4):325-32. PubMed ID: 9315472
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells.
Morimoto Y; Toyota M; Satoh A; Murai M; Mita H; Suzuki H; Takamura Y; Ikeda H; Ishida T; Sato N; Tokino T; Imai K
Br J Cancer; 2004 Feb; 90(4):844-52. PubMed ID: 14970863
[TBL] [Abstract][Full Text] [Related]
6. Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells.
Truax AD; Thakkar M; Greer SF
PLoS One; 2012; 7(4):e36013. PubMed ID: 22563434
[TBL] [Abstract][Full Text] [Related]
7. Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells.
Croce M; De Ambrosis A; Corrias MV; Pistoia V; Occhino M; Meazza R; Giron-Michel J; Azzarone B; Accolla RS; Ferrini S
Oncogene; 2003 Oct; 22(49):7848-57. PubMed ID: 14586411
[TBL] [Abstract][Full Text] [Related]
8. Expression of estrogen receptor alpha, retinoic acid receptor alpha and cellular retinoic acid binding protein II genes is coordinately regulated in human breast cancer cells.
Lu M; Mira-y-Lopez R; Nakajo S; Nakaya K; Jing Y
Oncogene; 2005 Jun; 24(27):4362-9. PubMed ID: 15870697
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.
Radosevich M; Song Z; Gorga JC; Ksander B; Ono SJ
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3185-95. PubMed ID: 15326139
[TBL] [Abstract][Full Text] [Related]
10. The major histocompatibility complex class II transactivator is differentially regulated by interferon-gamma and transforming growth factor-beta in microglial cells.
Pazmany T; Tomasi TB
J Neuroimmunol; 2006 Mar; 172(1-2):18-26. PubMed ID: 16360884
[TBL] [Abstract][Full Text] [Related]
11. IFN-gamma regulation of class II transactivator promoter IV in macrophages and microglia: involvement of the suppressors of cytokine signaling-1 protein.
O'Keefe GM; Nguyen VT; Ping Tang LL; Benveniste EN
J Immunol; 2001 Feb; 166(4):2260-9. PubMed ID: 11160280
[TBL] [Abstract][Full Text] [Related]
12. IL-1 beta inhibits IFN-gamma-induced class II MHC expression by suppressing transcription of the class II transactivator gene.
Rohn W; Tang LP; Dong Y; Benveniste EN
J Immunol; 1999 Jan; 162(2):886-96. PubMed ID: 9916712
[TBL] [Abstract][Full Text] [Related]
13. [Major histocompatibility complex class II transactivator (CIITA) hammer- head ribozyme transfer inhibits major histocompatibility complex class II (MHC-II) expression in Jukart cells].
Guo R; Zou P; Song YP; Ma J; Lu HZ; Cao YL; Tong YJ
Zhonghua Er Ke Za Zhi; 2003 Dec; 41(12):925-8. PubMed ID: 14723817
[TBL] [Abstract][Full Text] [Related]
14. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.
Soos JM; Krieger JI; Stüve O; King CL; Patarroyo JC; Aldape K; Wosik K; Slavin AJ; Nelson PA; Antel JP; Zamvil SS
Glia; 2001 Dec; 36(3):391-405. PubMed ID: 11746775
[TBL] [Abstract][Full Text] [Related]
15. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.
Lu HT; Riley JL; Babcock GT; Huston M; Stark GR; Boss JM; Ransohoff RM
J Exp Med; 1995 Nov; 182(5):1517-25. PubMed ID: 7595221
[TBL] [Abstract][Full Text] [Related]
16. Class II transactivator (CIITA) promoter methylation does not correlate with silencing of CIITA transcription in trophoblasts.
Holtz R; Choi JC; Petroff MG; Piskurich JF; Murphy SP
Biol Reprod; 2003 Sep; 69(3):915-24. PubMed ID: 12748124
[TBL] [Abstract][Full Text] [Related]
17. Correlation of class II transactivator with HLA-DR antigen and its implications.
Xu KL; Li H; Pan XY; Li ZY; Lu QX; Zhang Y; Zhu HH; DU B; Zeng LY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):147-51. PubMed ID: 17490542
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas.
Kanaseki T; Ikeda H; Takamura Y; Toyota M; Hirohashi Y; Tokino T; Himi T; Sato N
J Immunol; 2003 May; 170(10):4980-5. PubMed ID: 12734341
[TBL] [Abstract][Full Text] [Related]
19. RB and a novel E2F-1 binding protein in MHC class II deficient B-cell lines and normal IFN-gamma induction of the class IL transactivator CIITA in class II non-inducible RB-defective tumor lines.
Tschickardt ME; Lu Y; Jacim M; Ussery GD; Steimle V; Mach B; Blanck G
Int J Cancer; 1995 Aug; 62(4):461-5. PubMed ID: 7635572
[TBL] [Abstract][Full Text] [Related]
20. A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways.
Zhan Y; Zhang Y; Liu C; Zhang J; Smith WW; Wang N; Chen Y; Zheng L; He L
Cancer Prev Res (Phila); 2012 Jun; 5(6):864-73. PubMed ID: 22496388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
